y e a r s received b a i l y GHRH 20 uglkg sc + placebo.The c h i l d r e n were admitted t o t h e h o s p i t a l before and a f t e r 1 year of treatment t o meassure G H every 20 minutes f o r 24 hours and height was determined every 6 months. Growth v e l o c i t y increased i n group A from 3 . 3 5 0.6 cm/year t o 6.7 ?: 1.2 cm/year (p<0.0005) and i n group B from 3.2 2 0 . 8 cm/year t o 5.4 2 1.4 cm/year (p<0.025). Growth v e l o c i t y was s i g n i f i c a n t l y d i f f e r e n t i n group A compared t o group B (pc 0.05). Mean 24 hour G H s e c r e t i o n increased i n group A from 1 . 8 ?: 1.1 t o 2.221.2 ng/ml (NS) and i n group B from 1.2 2 0.14 t o 1.6 2 0.4 ng/ml (NS).This study demonstrate t h a t t h e beta-adrenergic blockade with Atenolol enhances t h e growth v e l o c i t y t o GHRH i n GHD c h i l d r e n .
This suggests t h a t t h e growth v e l o c i t y i n GHD c h i l d r e n t r e a t e d with GHRH can be p o t e n t i a t e d with an agent t h a t blocks Somatostatin s e c r e t i o n . To study t h e influence of IGF-1 and IGF-2 l e v e l s i n t h e catch-upgrowth(CUG) of small f o r g e s t a t i o n a l age (SGA) i n f a n t s , we followed 32 newborns (18 boys and 14 g i r l s ) with b i r t h weight of 2344c_195 g and b i r t h length of 45.7 2 2 cm. during t h e f i r s t year of 1ife.We measured weight. lenght. IGF-1 and IGF-2 a t 0. 3.6.9 and 12 months of age. CUG was defined a s an increase i n lenght 2 score g r e a t e r than 1 SD a t 6 months of age. based upon t h e f a c t t h a t accelerated growth. when observed i n CUG (+) i n f a n t s . occurs during t h i s period. W e compared t h e concentrations of IGF-1 and 2 between the i n f a n t s who demostrated evidence of CUG and those who did not. Results:
IGF-2 (pg/ml) N&/ 0 ~~~+ 1 6 1 0 / 8 3 1 .~5 . 2 189.5:_110.1 123.7232.5 138.7:34.9 1 0 8 . e 3 2 . 6 cug-16 8/8 1 6 . 1 5 4 . 4 1 2 0 . 9 f l . 9 9 3 . 9 9 . 126.3528.6 117.5239.4 P-NS Pc0.05 Pc0.02 PINS P-NS Height Z score was lower i n CUG(+)infants a t b i r t h and increased during the f i r s t 6 months of 1ife.IGF -2 l e v e l s were s i g n i f i c a n t l y g r e a t e r a t 3 and 6 months i n CUG ( + ) i n f a n t s . These were no d i f f erences i n IGF-2 l e v e l s a t 0. 9. 12 months. nor i n IGF-1 l e v e l s a t any time. W e conclude t h a t c i r c u l a t i n g IGF-2 l e v e l s a t 3 and 6 months c o r r e l a t e with height v e l o c i t y . This growth f a c t o r may be involved i n t h e mechanism of CUG i n SGA age i n f a n t s . This suggests t h a t IGF-2 may be u s e f u l a s a p o t e n t i a l therapeutic agent f o r the treatment of SGA i n f a n t s who do n o t demostrate evidence of CUG. Financial support: Grant 91-1274. Fondecyt.
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TRXATHENT OF CHRONIC RENAL FAILURE WITH GROWTH-HORMONE-RELEASING
HORMONE. T. Pasqualini. S. Moyano. P. Fainsteins-Day, R. Gutman. A. Eymann. J. F e r r a r i s . Hospital I t a l i a n o . Departamento de P e d i a t r i a . Buenos Aires. Argentina.
Growth r e t a r d a t i o n is common i n c h i l d r e n with chronic r e n a l f a i l u r e (CRF) and a f t e r r e n a l t r a n s p l a n t a t i o n (Tx). For t h i s reason we t r e a t e d 9 c h i l d r e n ( 3 on conservative treatment. CT; 3 on d i a l ys i s . D; and 3 Tx), aged 1.6 t o 14.0 (xzsd; 8.1 2 4.3) y e a r s , with twice d a i l y subcutaneous i n j e c t i o n s of growth -hormone-releasing analogue. GHRH (1-29)NH2 Serono a t a mean dose of 2657 ug/kg/day, during 2 t o 6 months. Mean serum urea and c r e a t i n i n e remained s t a b l e . although i n CT p a t i e n t s serum c r e a t i n i n e increased moderat e l y . Before treatment. mean bone age was 5.2 2 3.1 years. height SDS -2 . 2 5 . 6 and growth v e l o c i t y 4.522.9 cmlyear (-2.322.0 DS f o r chronological a g e ) . Mean nocturnal spontaneous growth hormone (xGH) was 3.321.6 ng/ml, smooth l i n e 1.6+0.9 nglml. amplitude 5.452.6 ng/ml. number of peaks 3.821.3 and growth hormone (GH) response t o GHRH t e s t (1 ug/kg IV) 61.7552.5 ng/ml. Five p a t i e n t s , a l l 3 on CT included, increased t h e h e i g h t v e l o c i t y from 3.851.6 t o 8.052.6 cm/year. The peak G H response t o GHRH was s i g n i f i c a n t l y higher i n t h e group of growth non-responders t h a n t h e responders (~~0 . 0 5 ) . Conclusion: GHRH treatment increased growth v e l o c i t y i n 55% of our p a t i e n t s . A l l CT p a t i e n t s had a worthwhile response t o therapy: h e i g h t ' v e l o c i t y increased by more than 2 cm/year. Growth response t o GHRH was lower when G H response t o GHRH t e s t was high. suggest i n g p e r i p h e r a l r e s i s t a n c e t o t h e b i o l o g i c a l a c t i o n of GH.
EVALUATION OF EFFICACY AND SAFETY OF RECOMBINANT HLMAN GROWTH HORMONE (rhGH) I N PRE-PUBERTAL SHORT CHILDREN WITH CHRONIC RENAL FAILURE (CRF). MCS. Boguszewski. R. Sandrini. I. Cat and L. de Lacerda. Division of Endocrine DeDt of P e d i a t r i c s . WPR. Curitiba. Paranh. B r a z i l .
Growth r e t a r d a t i o n is a common problem i n c h i l d r e n with CRF more pronounced t h e e a r l i e r t h e r e n a l f a i l u r e occurs. This study was designed t o evaluate t h e e f f i c a c y and s a f e t y of rhGH treatment i n pre-pubertal childrem with CRF and s h o r t s t a t u r e . 10 p a t i e n t s ( 5 g i r l s aged 5.9-11.5.mean 8 . 1 and 5 boys aged 3.8-12.2.mean 8.0)were a n r o l l e d i n t h e study according t o t h e following c r i t e r i a : CRF diagnosed a t l e a s t 12 months p r i o r t o e n t r y i n t o t h e study;glomerul a r f i l t r a t i o n r a t e (GRF) 50 ml/min/1.73m2 body surface a r e a (Schwartz's formula) and normal t h y r o i d function. rhGH (Genotropon (R). 1 IU/kg/week was given i n d a i l y s c i n j e c t i o n s f o r 12 months. C l i n i c a l and biochemical assessment was c a r r i e d o u t every 3 months. Mean height v e l o c i t y (HV)increased from 4 . 5 t o 8.6cm/year (~~0 . 0 1 ) ; mean HV -SDS increased from -1.58 t o 2.92 (pc0.01); mean height SDS improved from -3.3 t o -2.8(p<0.01).Mean weight gain was 3.2kg and mean bone age advanced 1 year. Two g i r l s s t a r t e d puberty a f t e r 6 months of therapy. GRF increased s i g n i f i c a n t l y (p<0.05) a t 6 months and returned t o pre-treatment values a t 1 year of therapy. Serum phosphate and i n s u l i n increased (p<0.01)at 12 months. Other biochemical paremeters (calcium, a l k a l i n e phosphatase. creatinine.T3. T4. TSH, hematocrit, c h o l e s t e r o l . t r y g l y c e r i d e s . Na. K. BUN. glucose and frutosamine)did n o t change.No s i d e e f f e c t s were observed. These r e s u l t s confirm previous r e p o r t s on t h e e f f e c t i v e n e s s of rhGH i n i n c r e a s i n g h e i g h t v e l o c i t y of s h o r t slowly growing p a t i e n t s with CRF .
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ANDROGEN PATTERN I N PREPUBERTAL HYPERTRICKSIS. H. Gryngarten. ME. Escobar. S. Campo. S. Ayuso. P. Bedecarrds. C. Bergad6. CEDE. Divisibn de Endocrinologia. Hospital de Nifios R. Gutierrez. Buenos Aires. Argentina.
The cause of prepubertal h y p e r t r i c h o s i s (H) is unknown. Plasmatic
androgen l e v e l s were determined i n 17 g i r l s with ti. (car X+SD: 5.521.41 y e a r s ) .
11 g i r l s with precocious pubarche (PP) and 9 normal prepubertal g i r l s (CP) .
A l l of them were assesed according t o t h e i r d i s t r i b u t i o n score of v e l l u s h a i r . Group H. was characterized by excessive growth of v e l l u s h a i r (score>7).CP showed normal d i s t r i b u t i o n and PP group had pubic h a i r 11-111 without excessive growth of v e l l u s h a i r (score<5)170H Pr0geSterone.AndroStenedione (A).DHEA-S.Testosterone(T).SHBG and 3 Androstanediol glucoronide(3 AG)were measured by RIA.
Normal l e v e l s of A and DHEA-S and elevated 3 A G l e v e l s suggest an increase i n t h e p e r i p h e r a l a c t i v i t y of 5 reductase i n most prepub e r t a l g i r l s with hypertrichosis. we' analyzed the molecular genetics and biochenkw of 5u:reductase 2 (5a-RD 2) ueficiency in 7 patients with male pseudohermaphroditism. The diagnosis of 5a-RD 2 was kstablished by clinical data (all patients were born with ambiguous genitaiia-microphallus, perineal hypospadias and bifid scrotum and were raised as females unlil 6-15 y when they 
4
Siblings bVe found four d~fferent mutations in our patients. These results confirm the genetic helerogeneily of the 5a-RD 2. We conclude that in all patients studied mutalions in type 2 gene account for 5a-reductase 2 deliciency.
